Immune Dysfunction in Allergic Asthma
We are using anti-IgE to investigate the role of pulmonary mast cells in asthma.
|Study Design:||Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Basic Science
|Official Title:||Not a Drug Trial. We Are Using Anti-IgE to Examine the Role of Pulmonary Mast Cells in Asthma|
- anti-KLH antibody [ Time Frame: 6 months ] [ Designated as safety issue: No ]Asthma and control patients are immunized with KLH
|Study Start Date:||September 2005|
|Study Completion Date:||June 2008|
|Primary Completion Date:||June 2008 (Final data collection date for primary outcome measure)|
This is not a drug study examining differences of therapeutic outcomes. It uses Xolair as an intervention that might change the outcome of immunization.
Patients are administered Xolair
Other Name: Xolair
Subjects with mild allergic asthma are examined before, immediately after and 2 months after a course of treatment with anti-IgE. The following are examined: Allergen skin tests, allergen induced asthma, peripheral blood basophils, pulmonary bronchial mucosal mast cells.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00189228
|United States, New Mexico|
|Albuquerque, New Mexico, United States, 87131|
|Study Director:||Mark Schuyler, MD||UNM HSC|